| scholarly article | Q13442814 |
| P2093 | author name string | Ahmad Tarhini | |
| Suzanne Lentzsch | |||
| Kenneth A Foon | |||
| Michael Boyiadzis | |||
| Louis Pietragallo | |||
| Mathew Sulecki | |||
| Stanley Marks | |||
| Patricia Kropf | |||
| Dhaval Mehta | |||
| Diana Lenzner | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| rituximab | Q412323 | ||
| P304 | page(s) | 3184-3185 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia | |
| P478 | volume | 119 |
| Q38579008 | Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). |
| Q38068932 | Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia |
| Q38700745 | Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? |
| Q46942326 | Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE"? |
| Q38424831 | Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial |
| Q52646820 | Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. |
| Q87869046 | Chronic lymphocytic leukaemia |
| Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
| Q47309947 | Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all? |
| Q40954148 | Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. |
| Q38061883 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). |
| Q38764077 | Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting |
| Q40662825 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri |
| Q37140685 | Immunotherapeutic approaches to hepatocellular carcinoma treatment |
| Q36498360 | Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia |
| Q36219647 | Initial treatment of CLL: integrating biology and functional status |
| Q91525913 | Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience |
| Q30243914 | Management of elderly and unfit patients with chronic lymphocytic leukemia |
| Q39169789 | Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia |
| Q53085579 | Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. |
| Q38601727 | Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope |
| Q90263221 | Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data |
| Q38862525 | Recent advances in therapy of chronic lymphocytic leukaemia |
| Q51007218 | Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. |
| Q46675870 | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience |
| Q37638782 | The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies |
| Q44579592 | Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. |
Search more.